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ABSTRACT
Two sensitive and reproducible methods were described for the quantitative determination of the antireteroviral drug ritonavir in the
presence of its degradation products. The first method was based on high performance liquid chromatographic (HPLC) separation of the
drug from its stress degradation products with the use of a reversed phase Agilent Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) and
a mobile phase consisting of acetonitrile : 0.05 M phosphoric acid (55 : 45, v/v) at a flow rate of 1.0 mL/min. The retention time of the
drug was found to be 4.82 ± 0.002 min. Quantification was achieved with diode array detection (DAD) at 210 nm based on peak area and
a linear calibration curve in the concentration range of 1-500 µg/mL. The proposed method made use of diode array detection as a tool for
peak purity and identification. The second method involved a high performance thin layer chromatographic (HPTLC) separation followed
by densitometric measurement of the spots at 240 nm. The separation was carried out on Fluka TLC aluminium sheets of silica gel with
fluorescent indicator (254) nm and the mobile phase was acetonitrile - water (1 : 2, v/v), adjusted to pH 5.0 using 1 M orthophosphoric acid
solution . The proposed procedure gave compact spots for ritonavir (retention factor, Rf = 0.41 ± 0.014). The linear regression equation
was generated by least-squares treatment of the calibration data in the range of 0.8-12.5 µg/spot. The reliability and analytical performance
of the proposed methods, including linearity, range, precision, accuracy, detection and quantitation limits, were statistically validated. The
proposed methods were applied to Norvir capsules and no chromatographic interference was observed. When ritonavir was subjected to
stress conditions; according to ICH guidelines, the proposed methods could effectively separate the drug from its degradation products,
and were thus considered as good stability-indicating procedures.
Key words: HPLC, HPTLC, ritonavir, soft gelatin capsules, stability-indicating

INTRODUCTION
Ritonavir (RIT, Figure 1) chemically known as [5S,8S,
10S,11S]-10-Hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)2,4,7,12-tetraazatridecan-13-oic acid 5-thiazolylmethyl
ester(1), is an antiretroviral drug from the protease inhibitor
class used to treat HIV infection and AIDS. RIT was originally developed as an inhibitor of HIV protease. It is one of
the most complex inhibitors and is now rarely used for its
own antiviral activity, but remains widely used as a booster
of other protease inhibitors(2,3). More specifically, RIT is used
to inhibit a particular liver enzyme that normally metabolizes
protease inhibitors, cytochrome P450-3A4. RIT is frequently
prescribed with antiretroviral drugs, not for its antiviral action,
but as it inhibits the same host enzyme that metabolizes other
* Author for correspondence. E-mail:rasha_shaalan@yahoo.com

protease inhibitors.
The analytical method for RIT is published in BP 2010(4)
and USP 2011(5) , in which the bulk powder is assayed
using HPLC. Literature on RIT determination focused on

Figure 1. Structure of Ritonavir (RIT).
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chromatographic methods, with HPLC as the predominant
method, and dealt with the determination of RIT in biological
fluids. Most of them are applied for the quantitation of RIT in
plasma(6-13), serum(14,15), salivary fluid and CSF(16). All these
HPLC methods depended on either mass spectrometric detection(6-10) or UV detection(10-13). Two novel methods were
reported using sub 2-µm particle columns(6,8), while most of
the methods made use of C18 columns(9,11-13).
Capillary electrophoresis was also one of the tools
applied for the separation of RIT from other protease inhibitors(17) or the quantitation of RIT in serum(18).
Several HPLC methods had been reported for the determination of RIT and most of them involved the quantification of RIT in biological fluids(6-16). However, none of them
suggested an application to its capsules. To our knowledge,
no article related to the stability-indicating chromatographic
determination of RIT in pharmaceutical dosage form has
been reported. Few methods studied the physical stability
of RIT(19-22) and only one method has discussed its chemical stability under different conditions(23). The ICH Q1A
guideline entitled “Stability testing of new drug substances
and products” requires that stress testing be carried out to
elucidate the inherent stability characteristics of the active
substance(24). The guidelines explicitly require conduct of
forced decomposition studies under a variety of conditions,
such as pH, light, oxidation and dry heat followed by separation of the drug from its degradation products. The method
is expected to allow the analysis of individual degradation
products. An ideal stability-indicating method is one that
quantifies the standard drug alone and also resolves its degradation products. Consequently, the implementation of an
analytical methodology to determine RIT in pharmaceutical
dosage form in the presence of its degradation products is
a pending challenge. Therefore, it was thought necessary
to study the stability of RIT towards acidic, alkaline and
oxidative degradation processes. The aim of this work was
to develop stability-indicating chromatographic methods for
the determination of RIT in the presence of its degradation
products for the assessment of the purity of the bulk drug
and the stability of its bulk dosage form using HPLC and
HPTLC-densitometry.
The first method was based on high performance liquid
chromatographic separation of the drug from its degradation
products using a reversed phase, Agilent Eclipse XDB-C18
column at ambient temperature. The second method was a
very viable stability-indicating one based on high performance thin layer chromatographic (HPTLC) separation
followed by densitometric measurement of the spots at
240 nm. The advantage of HPTLC is that several samples
could be run simultaneously using a small quantity of the
mobile phase system, thus reducing analysis time and cost
per analysis.

MATERIALS AND METHODS
I. Instrumentation

The HPLC-DAD system consisted of Agilent (Santa
Clara, CA, USA) 1200 series (quaternary pump, vacuum
degasser and diode array and multiple wavelength detector
G1315 and G 1365 C/D) connected to a computer installed
with Agilent ChemStation software. A rheodyne manual
injector with a 20-µL loop was used. The column used was
reversed phase Agilent Eclipse XDB-C18 (4.6 × 150 mm,
5 µm).
A CAMAG Linomat TLC-Applicator and a CAMAG
Linomat syringe (100 μL) were used for the application of
solutions onto silica gel/TLC cards (DC-Alufolien-Kieselgel
with fluorescent indicator 254 nm, layer thickness of 0.2 mm,
FlukaChemica®) of size 200 × 200 mm. The plates were
developed in CAMAG twin trough chromatographic tanks
(150 × 200 × 300), and scanned densitometrically using
CAMAG TLC-Scanner 3 (Version 4.06), supported with
UV-lamp short wavelength 254 nm and interfaced to an IBM
computer installed with CAMAG-TLC-Software (CATS).
II. Materials
The authentic sample of Ritonavir (RIT) was kindly
provided by Pharco Pharmaceuticals, Alexandria, Egypt.
Analytical grade orthophosphoric acid, sodium hydroxide,
hydrochloric acid and 30% hydrogen peroxide were used.
HPLC grade acetonitrile (LAB-SCAN analytical sciences,
Ireland) was used. Point forty-five micrometer cellulose
nitrate membrane filters (Sartorius Stedium Biotech GmbH
37070 Goettingen, Germany) were used. Norvir® capsules
labeled to contain 100 mg of ritonavir, (Abbott Diagnostics,
Austria) were assayed in this study.
III. General Procedures and Calibration Graphs
(I) HPLC Method
The mobile phase was prepared by mixing acetonitrile:
0.05 M Phosphoric acid (55 : 45, v/v). The mobile phase was
filtered and degassed by passing through a 0.45-µm pore size
membrane filter prior to use. The flow rate was 1.0 mL/min
and the injection volume was 20 µL, the eluent was monitored using diode array detection (DAD) from 190 nm to
400 nm, and chromatograms were recorded at 210 nm. All
determinations were performed at room temperature.
RIT stock standard solution (12.5 mg/mL) was prepared
in acetonitrile. RIT working standard solution (0.5 mg/mL)
was prepared by dilution of 1 mL of RIT stock standard
solution with acetonitrile into a 25-mL volumetric flask. The
working solutions were prepared by dilution of the standard
solutions with the mobile phase to obtain a concentration range
of 1-500 µg/mL. Triplicate 20-µL injections were made for
each concentration and chromatographed under the described
LC conditions. The peak areas were plotted against the corresponding concentrations to obtain the calibration curve.
(II) HPTLC Densitometry
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The final solutions were prepared by dilution of
accurate volumes of the RIT stock standard solution
(12.5 mg/mL) with acetonitrile to obtain a concentration
range of 0.8-12.5 µg/spot.
1. Sample Loading
The solutions were applied to the marked start edge of
the TLC plate at a height of 15 mm from the lower edge of the
plate using the specified TLC CAMAG linomat syringe. The
sample volume for all solutions was 5 µL and spotting was
performed in the form of bands of 6-mm width. Each solution
was applied in duplicate and allowed to air-dry for 15 min.

Table 1. Analytical parameters for the determination of RIT using the
proposed chromatographic methods
Parameter
Linearity Range
Intercept(a)
1

% y-intercept (Peak area at
100% target concentration)
Slope (b)
RSD% of slope
Correlation Coefficient(r)
Sa2

HPLC

HPTLC

1-500 (µg/mL)

0.8-12.5 (µg/spot)

46.78

1143.11

0.50 (9327.5)

12.35 (9255.4)

46.90

1622.46

0.21

1.12

0.99998

0.99968

20.91

123.24

Sb

3

0.01

18.16

Sy/x4

56.22

215.10

LOD

0.14 (µg/mL)

0.25 (µg/spot)

LOQ

0.47 (µg/mL)

0.76 (µg/spot)

y-intercept
×100
peak area at 100% target concentration
2
Sa: Standard deviation of intercept
3
Sb: Standard deviation of slope
4
Sy/x: Standard error

2. Chromatogram Development
The mobile phase used was acetonitrile-water in the
volume ratio 1 : 2, adjusted to pH 5.0 using 1 M orthophosphoric acid solution. Twenty milliliters of the mobile phase
were poured into the TLC chamber that was lined with a thick
filter paper on a single side to assist in the chamber saturation.
The chamber was covered with a lid and pre-saturated with
the mobile phase for 15 min at room temperature (25 ± 2°C).
The sample-loaded TLC plates were transferred to the
chamber and then developed ascendingly for not less than
18-cm of migration distance of the mobile phase from the
start line (approximately 40 min). The developed TLC plates
were air dried for about 15 min.
3. Chromatogram Scanning and Data Processing
The dried plates were densitometrically scanned
at 240 nm. The TLC chromatogram was captured by the
scanner and loaded into the CAMAG TLC software. In the
software, the series of spots were selected as tracks. Each
track was evaluated based on the position of the spot and its
peak area. Quantity calibration was then performed by preassignment of the concentration of the investigated drug.
The calibration graph correlated the concentration to the
corresponding peak area.
The accuracy and precision study was performed for
both HPLC and HPTLC by preparing three replicates for
three selected concentrations of RIT (Table 2). Aliquots
of the stock solution of RIT were diluted with the mobile
phase to reach the selected concentrations. Solutions were
either injected into the column, or applied to the TLC plate
and then assayed using the appropriate procedure, and the
recovered concentrations were calculated from the previously
constructed calibration graphs.

1

%y-intercept =

IV. Applications
(I) Forced Degradation and Stability Indicating Study of RIT

Table 2. Accuracy and precision for the analysis of RIT in bulk form using the proposed chromatographic methods
A) HPLC-DAD Method
Results

Intra-day(n = 9)

Concn.
Nominal value (µg/mL)

Found ± SD (µg/mL)

RSD (%)

Inter-day(n = 9)
Er(%)

Found ± SD (µg/mL)

RSD (%)

Er(%)

20

20.42 ± 0.059

0.29

2.01

20.36 ± 0.663

0.65

1.80

60

60.74 ± 0.555

0.91

1.24

60.97 ± 1.022

1.68

1.61

100

102.58 ± 0.424

0.41

2.58

102.67 ± 0.445

0.43

2.67

B) HPTLC Method
Results

Intra-day(n = 9)

Concn.

Inter-day(n = 9)

Nominal value (µg/spot)

Found ± SD (µg/spot)

RSD (%)

Er(%)

Found ± SD (µg/spot)

RSD (%)

Er(%)

1.0

1.01 ± 0.012

1.21

1.10

1.03 ± 0.026

2.54

2.95

2.5

2.48 ± 0.024

0.98

-0.70

2.53 ± 0.024

0.94

1.09

10.0

10.08 ± 0.123

1.22

0.81

10.18 ± 0.114

1.12

1.76
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1. Acidic and Basic Conditions (for HPLC and HPTLC)
RIT solutions were treated with 1 mL of 1 M methanolic
HCl or 1 M methanolic NaOH. A set of solutions was kept at
room temperature for 24 h and another set was placed in a
water bath at 85°C for 2 h. After the specified time intervals,
all solutions were neutralized by adjusting the pH to 7.0 and
then diluted with the mobile phase to reach a final concentration of 50 μg/mL of RIT.
2. Oxidation with H2O2 (for HPLC Only)
RIT solutions were treated with 1 mL of hydrogen
peroxide 30%. One solution was kept at room temperature
for 24 h and another was placed in a water bath at 85°C for
2 h. Both solutions were kept protected from light. After the
specified time intervals, the solutions were diluted with the
mobile phase to reach a final concentration of 50 μg/mL of
RIT. After the previous treatments, the solutions were filtered
with a 0.45-μm filtration disc prior to injection to the column.
(II) Assay of Norvir Capsules
Norvir® capsules are soft gelatin capsules that contain
100 mg of RIT. One capsule was punctured and the liquid
content was carefully squeezed into a beaker. The soft gelatin
shell was washed with acetonitrile into the beaker, sonicated
for 30 min and the solution was delivered quantitatively into
a 100-mL volumetric flask. The beaker was washed with
acetonitrile and the wash was transferred into the flask. The
volume was finally diluted to 100 mL with acetonitrile. For
HPLC, further dilutions were made to obtain solutions of final
concentration within the linearity range 1-500 µg/mL, and the
general procedure was then followed. For HPTLC, 5 µL of
Norvir® sample solution was applied to the plate concurrently
with RIT standard solution. The TLC plates were then treated
in a manner similar to the previously described procedure.

RESULTS AND DISCUSSION
I. HPLC Method
A stability-indicating HPLC-DAD method was developed to provide rapid and reliable quality control analysis of
RIT in soft gelatin capsules. The method involved the use of
RP-C18 column with isocratic elution using a mobile phase
consisting of acetonitrile : 0.05 M phosphoric acid (55 : 45,
v/v). Using a mobile phase flow rate of 1.0 mL/min, RIT
displayed typical peak characteristics at 210 nm with acceptable retention time ( tR = 4.82 min) (Figure 2). The proposed
method had the advantage of using a simple mobile phase
without the need for pH adjustment.

mAU

1.816

Forced degradation studies under different conditions were carried out on the RIT standard according to the
following conditions:

250
200
150
100
50
0
0

1

2

3

4

5

6

7

8

9

min

Figure 2. Typical HPLC chromatogram of a 20-µL injection of
60 µg/mL RIT at 210 nm.

(I) Optimization of Chromatographic Conditions
Several mobile phases were tried using various proportions of different aqueous phases and organic modifiers. The
best chromatogram was obtained using the above mentioned
mobile phase (Figure 2). Decreasing the acetonitrile content
in the mobile phase led to longer retention times and excessive peak tailing. Increasing the acetonitrile content yielded
a RIT peak that was very close to the solvent peak. Methanol
was tried as an organic modifier and different phosphoric acid
strengths were tried (0.025 and 0.075 M). Phosphoric acid
was substituted by acetic acid in some trials. In all these trials,
the chromatograms showed broad asymmetric peaks and/or
increased retention times and, consequently, fewer theoretical
plates for the eluted peaks. Quantitation was achieved using
DAD based on peak area measurements. RIT exhibits UV
absorption mainly below 260 nm. The previously described
chromatographic conditions showed symmetrical peaks
at 4.82 ± 0.002 min, with retention factor (K') of 1.86 and
column performance (apparent efficiency expressed by the
number of theoretical plates, N) of 5930. The resolution of
standard RIT in the presence of degradation products was
satisfactory. Ultimately, a mobile phase consisting of acetonitrile : 0.05 M phosphoric acid (55 : 45, v/v) was selected for
validation purposes and stability studies.
(II) Stability Indicating Aspects
According to ICH guidelines, forced degradation
experiments were carried out on RIT in order to produce the
possible relevant degradants and test their chromatographic
behavior using the optimized HPLC method.
Hydrolytic degradation studies using both strong acidic
and basic media as well as oxidative degradation studies on
RIT were conducted either at room temperature or with the
aid of heating. In strong acidic medium and with the aid of
heating, degradation of RIT was observed from the reduction of its peak area at 4.82 ± 0.002 min which decreased by
88% of the expected intact area and the appearance of a major
degradation peak at about 5.47 min. In comparison keeping
the drug in contact with HCl for a long period of time (24 h)
at room temperature resulted in limited degradation. In both
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cases, minor degradation products co-eluted with the solvent
peak at about 1.192 and 2.3 min. Figure 3A and 3B show the
chromatograms of RIT after treatment with 1 M HCl.
Similarly, sodium hydroxide attacked RIT and a major
degradation product peak eluted at about 5.47 min. Other
minor degradation products peaks eluted in the time range
between 1.2 and 1.8 min. Degradation increased when the
drug solution was kept in contact with NaOH for 24 h at room
temperature observed from the peak areas of RIT at 4.82 ±
0.002 min and that of the major degradation peak at 5.47 min
(Figure 4A and 4B).
It was noteworthy to mention that the major degradation
peak eluted at 5.47 min for both acidic and basic degradation
in which an absorption spectrum very similar to that of the
RIT intact drug was observed. This suggested that the drug

chromophore was not altered. In a previous report discussing
the stability of RIT using LC-MS-MS(23), it was reported that
the drug was degraded due to the presence of carbamate and
urea linkage, which were susceptible to hydrolysis.
The situation was different in the case of oxidative
degradation. RIT was relatively resistant to degradation
with hydrogen peroxide at room temperature as indicated
from its peak area compared to that of the standard of the
same concentration, while upon heating at 80 ± 5°C for 2 h,
RIT underwent degradation up to 82%. Figures 5A and 5B
illustrate the chromatograms of RIT after treatment with 30%
hydrogen peroxide.
In all these forced degradation experiments, RIT was
successfully separated from all the degradation products
as confirmed by the resolution values calculated for each
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Figure 3. HPLC chromatograms of 50 µg/mL RIT after exposure to
acid degradation with the aid of heating (A) and at room temperature
(B).
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Figure 4. HPLC chromatograms of 50 µg/mL RIT after exposure to
alkaline degradation with the aid of heating (A) and at room temperature (B).
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Figure 5. HPLC chromatograms of 50 µg/mL RIT after oxidative degradation with the aid of heating (A) and at room temperature (B).
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chromatogram (> 2). In addition, the identity and purity of
RIT were confirmed with the use of DAD, and no signs of
co-elution from any of the degradation products was detected.
II. HPTLC-Densitometric Method
The present work is concerned with the application of
the HPTLC densitometric technique in the determination of
RIT in its pure form and in capsules. The initial method development was conducted on the pure drug using a working standard solution. A number of preliminary trials were performed
to establish the final chromatographic conditions. Different
mobile phase systems were tested, including acetonitrile/
methanol (1 : 1, v/v), acetonitrile/water (1 : 2, v/v) and acetonitrile/phosphate buffer in three different ratios. Acetonitrile/
water (1 : 2, v/v) adjusted to pH 5 was found to give optimum
separation between pure RIT and its degradation products.
The effect of pH on the separation ability of the mobile phase
was investigated by changing the pH from 3 to 6 at one
pH unit interval. The best resolution and sharp peaks were
obtained at pH 5.0. In addition, the proportion of acetonitrile

in the mobile phase was changed from 10 to 70%, and the
best results were obtained using acetonitrile/water (1 : 2, v/v).
The proposed procedure gave compact spots for RIT with an
Rf of 0.41 ± 0.01 (Figure 6).
(I) Stability Indicating Aspects
An ideal stability-indicating assay method is one that
quantifies the standard drug alone and resolves its degradation
products. As described in the experimental section different
stress conditions were applied, including acidic and alkaline
degradation.
The densitogram of the acid-degraded RIT solution
under heating conditions showed two degraded peaks at
Rf = 0.68 and Rf = 0.75 (Figure 7). The concentration of the
drug was found to change from the initial concentration as
confirmed by a reduction in the peak area by 75% of the
expected response, hence indicating that RIT undergoes
degradation under acidic conditions.
On the other hand, degradation in acidic medium at room
temperature for 24 h showed reduced degradation. Only one

AU 300
250
200
150
100
50
0
-0.06

0.14

0.34

0.54

0.74

0.94

Rf

0.74

0.94

Rf

Figure 6. Densitogram of standard RIT (7.5 µg/spot-5-µL band), peak 1 (Rf = 0.41 ± 0.01).

AU 300
250
200
150
100
50
0
-0.06
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0.34

0.54

Figure 7. Densitogram of acid (1 M HCl, 80° C for 2 h)-treated RIT (2.5 µg/spot); peak 1 (standard, Rf = 0.41), peak 2 (degraded, Rf = 0.68), peak
3 (degraded, Rf = 0.75).
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additional peak appeared at Rf = 0.60 (Figure 8), and the peak
area of the intact RIT drug suffered from only 10% reduction.
The samples degraded in alkaline medium, with the aid
of heating at 80°C for 2 h, showed additional peaks at Rf
values of 0.55 and 0.73 (Figure 9). The spots of the degraded
products were well-resolved from the drug spot. Similarly,
the densitogram of the alkaline-degraded RIT solution at
room temperature for 24 h (Figure 10) showed an additional
spot at Rf = 0.73. The reduction in the peak area was almost
up to 80%. The above experimental findings indicate that RIT
is susceptible to acid-base hydrolysis. The higher Rf values of
acid and base-degraded components indicated that they were
more polar than the analyte itself.
III. Statistical Analysis of Results
(I) Concentration Ranges and Calibration Graphs
Under the optimal experimental chromatographic conditions, linear relationship exists between the integrated peak area

AU

and the corresponding concentration of RIT. The performance
data and statistical parameters including linear regression
equations, concentration ranges, correlation coefficients (r)
and other statistical parameters such as the standard deviations of the intercept (Sa), the slope (Sb) and standard deviations of residuals (Sy/x) are listed in Table 1 for both the HPLC
and HPTLC methods. Regression analysis for the calibration
curves showed good linear relationships over the concentration range of 1-500 µg/mL as judged by the correlation coefficient value (r = 0.99998) for HPLC and over the concentration range of 0.8-12.5 µg/spot as judged by the correlation
coefficients value (r = 0.99968) for HPTLC, the RSD% of
slope did not exceed 0.21 and 1.12% for HPLC and HPTLC,
respectively, and the y-intercept values were less than 2% of
the response for the target value of the analyte(25).
Unlike HPLC methods, for which linearity of detector
response over a wide range of concentration of analyte can
be obtained, the calibration curve of UV-detector response
versus a wide range of concentration for HPTLC often
does not follow linear regression. With HPTLC, the analyte

300
250
200
150
100
50
0
-0.06

0.14

0.34

0.54

0.74

0.94

Rf

Figure 8. Densitogram of acid (1 M HCl, ambient temperature for 24 h)-treated RIT (2.5 µg/spot); peak 1 (standard, Rf = 0.41), peak 2 (degraded,
Rf = 0.60).
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Figure 9. Densitogram of base (1 M NaOH, 80°C for 2 h)-treated RIT (2.5 µg/spot); peak 1 (standard, Rf = 0.41), peak 2 (degraded, Rf = 0.55), peak
3 (degraded, Rf = 0.73).
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Figure 10. Densitogram of base (1 M NaOH, ambient temperature for 24 h)-treated RIT (2.5 µg/spot); peak 1 (standard, Rf = 0.41), peak 2
(degraded, Rf = 0.73).

interacts with the surface of the stationary phase where scattering and absorption tend to take place with high concentration of analyte(26).

results performed on the same day and on three consecutive
days showed good precision and accuracy as indicated by the
RSD% and Er% values (Tables 2A and 2B).

(II) Detection and Quantitation Limits

(IV) Robustness

The limit of detection (LOD) was defined as the concentration which has a signal-to-noise ratio of 3 : 1. For the limit
of quantitation (LOQ), the ratio considered was 10 : 1. The
LOD and LOQ values of RIT are given in Table 1. The LOQ
value was verified by its nearness to the lower concentration
of the working range (1 µg/mL) for HPLC. Both LOD and
LOQ values confirmed the sensitivity of the proposed HPLC
procedure.
For HPTLC, the limit of detection (LOD) and the
limit of quantitation (LOQ) were mathematically calculated
according to the formulae(27):

The robustness of an analytical procedure is a measure
of its capability to remain unaffected by small but deliberate
variations in method parameters. This was performed in the
case of the HPLC method by making small changes in the
mobile phase composition (± 2%), flow rate (± 0.1 mL/min)
and working wavelengths (± 2 nm). These variations did not
have any significant effect on the measured responses or the
chromatographic separation. The RSD% of the measured
peak areas for the studied variations were found to be 0.23,
0.48 and 0.66 when changing the mobile phase composition,
flow rate and working wavelength were changed, respectively. The studied changes in the case of HPTLC were the
acetonitrile content in the mobile system (± 10%) and the
time for saturation of the development chamber (± 5 min).
The RSD % of the measured peak areas for the studied variations was found to be 0.77 and 0.90, respectively.

LOD =

3.3 × σ
S

LOQ =

10 × σ
S

where σ is the standard error and S is the slope of the
calibration plot. These values are presented in Table 1 and
indicated high sensitivity of the proposed HPTLC method.
(III) Precision and Accuracy
The precision and accuracy were examined at three
concentration levels for the analyte (20, 60 and 100 µg/mL
for HPLC; 1.0, 2.5 and 10.0 µg/spot for HPTLC) and five
replicate determinations for each concentration. The assay

(V) Specificity and Selectivity
Specificity of the HPLC and HPTLC methods were
assessed by comparing the chromatograms obtained from
standard solutions with those obtained from sample solutions of capsules. As the retention time tR and Rf values of
the standard drug and the drug in the capsule test solution
were the same, this indicated that the methods were specific.
On the other hand, the use of photodiode array detector in the
case of HPLC allowed the confirmation of the specificity of
the method by comparison with the reference drug spectrum.
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Figure 11. UV spectra of the HPTLC eluted peak due to RIT at the peak start, apex and peak end.

In addition the peak purity of RIT was assessed in the case
of HPTLC by comparing its respective spectra at the peak
start, apex and peak end positions of the spot (Figure 11).
The specificity of the method was performed by analyzing the
drug standard and sample solutions of capsules. The spot of
RIT was compared with its Rf values in both cases.
Selectivity was demonstrated by the separation of RIT
from forced degradation products and formulation additives
in both methods. The use of the photodiode array detector
in HPLC allowed the confirmation of the selectivity of the
method by comparison with the reference drug spectrum.
The method proved to be selective in the separation of the
investigated drug. Selectivity was also demonstrated by the
separation of RIT from forced degradation products and
formulation additives.
To check the selectivity of the proposed HPTLC
method, the ability of the mobile phase to resolve the major
compound from possible degradation products was tested.
A sample containing the forced degradation solution was
applied to the plate and analyzed concurrently with two
different concentrations of the intact standard solutions. The
results revealed that the proposed method could completely
discriminate the major intact drug from the forced degradation products, hence proving the selectivity of the method.
(VI) Stability of Standard and Sample Solutions
The stability of the working solutions of the analyte in the
HPLC mobile phase was examined, and no chromatographic
changes were observed within 5 h at room temperature. In
the case of HPTLC, there was no indication of compound
instability in the sample solution, when the freshly-prepared
solutions and those stored under refrigeration (4°C) for 12
h, 24 h and 7 days were applied on the same HPTLC plate.
The densitograms were evaluated after development and no

Table 3. Application of the proposed chromatographic methods for
the determination of RIT in Norvir® soft gelatin capsules
Method
Results
%Recovery ± SDa

HPLC
method

Comparison
referee methodd

HPTLC
method

98.03 ± 0.71

98.34 ± 0.61

97.34 ± 0.77

b

0.72

0.62

0.79

Er%c

-1.97

-1.66

-2.66

Variance (S2)

0.50

0.37

0.59

RSD%

t-calculated

0.73

2.27

F-calculated

1.32

1.56

a

Mean % recovery ± SD for five determinations.
b
% relative standard deviation.
c
% relative error.
d
Comparison Referee HPLC method(11).
Theoretical values for t and F at P = 0.05 are 2.31 and 6.39, respectively.

additional spots were detected. The stock solutions were
stable for at least one week when kept under refrigeration.
IV. Assay of Capsules
The developed stability-indicating HPLC and HPTLC
procedures were applied for the assay of RIT in soft gelatin
capsules. Table 3 shows the results obtained for the proposed
methods and a comparison referee HPLC method(11). The
results obtained by the proposed methods were statistically
compared with those of the comparison referee method using
the Student’s t-test and the variance ratio F-test. The calculated t- and F-values did not exceed the theoretical values
which indicated a good agreement between the proposed
and comparison referee methods. No interfering peaks were
observed in the chromatograms or densitograms of RIT
capsules.
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CONCLUSIONS
A simple and rapid HPLC-DAD assay method has been
developed for the quality- control and quantitation of RIT
capsules. The method can be used to determine concentrations as low as 1 µg/mL. It can also be used as a quality
control tool to monitor the exact content of RIT capsules.
Moreover, the method was extended to study the degradation
behavior of RIT under stress hydrolytic and oxidative conditions. Few reports were published concerning the degradation behavior of RIT and its forced degradation products, of
which, one recent report used LC-MS-MS(23). The current
study is comparable to the reported work(23). In addition, the
active pharmaceutical ingredient eluted earlier at 4.82 min in
the proposed study compared to 9.0 min.
The proposed HPTLC method is simple, accurate and
stability-indicating as it separates the drug from its degradation products. The method was used for the determination of
RIT in soft gelatin capsules, without any interference from
excipients and in the presence of its acidic and alkaline degradation products. The chromatographic method was validated
as per ICH guidelines. The HPTLC method uses a minimal
volume of solvents and is suitable for use in quality control
laboratories where time and cost are factors of concern.
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